is semaglutide in short supply shortage ends as FDA sets deadline for compounders Hims & Hers can't sell

Reports circulating in early 2026 of a broad move of Category 2 peptides back toward Category 1, and specific vendor claims that BPC-157 was "removed" from Category 2 in April 2026, could not be confirmed from an authoritative FDA source and are not treated as fact here

While the second mutant is missing the first three amino acids of IGF-1 (IGF-1 DES) and was named knock-in D (KID)

Brief temperature excursions (a few hours at room temperature) typically cause minimal potency loss

The medication is widely prescribed for diabetic neuropathy and peripheral neuropathy due to its ability to repair and protect nerves